Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022
June 10, 2022 03:00 ET
|
Imago Biosciences, Inc.
- The study completed enrollment with 73 patients in April 2022 - - As of the data cutoff of 29 April 2022, bomedemstat demonstrated durability of response with 81% of patients achieving normalized...
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022
June 10, 2022 03:00 ET
|
Imago Biosciences, Inc.
- As of the data cutoff date of 29 April 2022, in addition to improvements in the standard metrics of spleen volume reduction and symptom scores, long term treatment with bomedemstat showed: 52% had...
Imago BioSciences to Host Virtual Investor Event
June 06, 2022 17:24 ET
|
Imago Biosciences, Inc.
- Company to host virtual investor event on Saturday, June 11 at 10:30 AM ET following its June 10th presentation of updated data from Phase 2 studies of bomedemstat for the treatment of Essential...
Imago BioSciences to Participate in Upcoming Investor Conferences
May 16, 2022 08:00 ET
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines...
Imago BioSciences Reports First Quarter 2022 Financial Results and Provides Recent Business Updates
May 12, 2022 16:05 ET
|
Imago Biosciences, Inc.
- Completed Type C meeting with FDA to align on study design, study population, control group and primary endpoint for planned Phase 3 essential thrombocythemia (ET) study - Enrollment completed in...
Imago BioSciences Announces Upcoming Presentations on Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at the 27th Congress of the European Hematology Association (EHA) for 2022
May 12, 2022 08:00 ET
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines...
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer
May 09, 2022 08:00 ET
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines...
Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia
May 03, 2022 08:00 ET
|
Imago Biosciences, Inc.
Interim Data Update at European Hematology Association (EHA) meeting in June and Results from Completed Phase 2 Study Expected in Second Half of 2022 End-of-Phase 2 Meeting with U.S. Food and...
Imago BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results
March 24, 2022 16:05 ET
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...
Imago BioSciences Appoints Michael Arenberg to Chief Operating and Business Officer
March 23, 2022 16:05 ET
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...